4//SEC Filing
Cavu Advisors, LLC 4
Accession 0001104659-24-065619
CIK 0001763950other
Filed
May 27, 8:00 PM ET
Accepted
May 28, 4:31 PM ET
Size
25.1 KB
Accession
0001104659-24-065619
Insider Transaction Report
Form 4
Kreis Leslie W.
10% Owner
Transactions
- Sale
Common Stock
2024-05-23$6.25/sh−930$5,813→ 59,326 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-23$6.25/sh−6,944$43,400→ 443,174 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−2,126$13,288→ 135,706 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-05-24$6.33/sh−1,859$11,767→ 57,467 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−13,888$87,911→ 429,286 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-24$6.33/sh−4,253$26,921→ 131,453 total(indirect: By Bios Fund II, LP)
Holdings
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
Cavu Advisors, LLC
10% Owner
Transactions
- Sale
Common Stock
2024-05-23$6.25/sh−6,944$43,400→ 443,174 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−2,126$13,288→ 135,706 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-05-23$6.25/sh−930$5,813→ 59,326 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−4,253$26,921→ 131,453 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-05-24$6.33/sh−1,859$11,767→ 57,467 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−13,888$87,911→ 429,286 total(indirect: By Bios Fund II QP, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
Cavu Management, LP
10% Owner
Transactions
- Sale
Common Stock
2024-05-24$6.33/sh−1,859$11,767→ 57,467 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−13,888$87,911→ 429,286 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−930$5,813→ 59,326 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-23$6.25/sh−6,944$43,400→ 443,174 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−2,126$13,288→ 135,706 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-05-24$6.33/sh−4,253$26,921→ 131,453 total(indirect: By Bios Fund II, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
BP Directors, LP
10% Owner
Transactions
- Sale
Common Stock
2024-05-23$6.25/sh−930$5,813→ 59,326 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−1,859$11,767→ 57,467 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-05-24$6.33/sh−4,253$26,921→ 131,453 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-05-24$6.33/sh−13,888$87,911→ 429,286 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−6,944$43,400→ 443,174 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-05-23$6.25/sh−2,126$13,288→ 135,706 total(indirect: By Bios Fund II, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. On May 23, 2024 each of Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $6.08 to $6.49, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. On May 24, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $6.15 to $6.64, inclusive.
- [F3]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
- [F4]Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- [F5]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001813310
Filing Metadata
- Form type
- 4
- Filed
- May 27, 8:00 PM ET
- Accepted
- May 28, 4:31 PM ET
- Size
- 25.1 KB